Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

A Phase I and Pharmacokinetic Study to Evaluate Histone Deacetylase Inhibitor, Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

The purpose of this study is to evaluate the safety and tolerance of entinostat administered orally as a single agent in a weekly dosing schedule. Additionally, this study will characterize the pharmacokinetics parameters in Chinese postmenopausal women with advanced breast cancer. And to define the profile of adverse events, including laboratory parameters in these subjects

Study Overview

• Status: Completed
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Entinostat; Drug: Exemestane

• Study Type: Interventional
• Enrollment (Actual): 19
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100021
      • Cancer Hospital Chinese Academy Medical Sciences
  • Hunan
    • Changsha, Hunan, China, 410013
      • Hunan Cancer Hospital
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • West China Hospital
  • Tianjin
    • Tianjin, Tianjin, China, 300000
      • Tianjin Medical University Cancer Institute & Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

For inclusion in the study patients should fulfil the following criteria:

• Provision of informed consent prior to any study specific procedures.
• Postmenopausal women aged ≤ 65years.
• Estrogen receptor (ER) and / or progesterone receptor (PR) positive breast cancer confirmed by pathology.
• Once received a non-steroidal aromatase inhibitor (letrozole / anastrozole) treatment, the disease recurrence or progression of breast cancer currently.
• Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. And recently (past 2 months), weight loss is no more than 10% of average weight.
• Patients must have a life expectancy >3 months.

• Patients must have adequate organ and bone marrow function as defined by the following laboratory results.

  1. .absolute neutrophil count ( ANC )≥ 1,500 /mm3
  2. . Platelets≥100,000 /mm3
  3. . White blood cell count(WBC） ≥ 3,000 /mm3
  4. . Hemoglobin ≥ 9 g/dL.
  5. . Creatinine ≤ 1.5 times the upper limit of normal (ULN) for the institution or Creatinine clearance ≥ 60 ml/min/1.73m2
  6. . Total bilirubin ≤ 1.5 times the upper limit of normal for the institution(ULN)
  7. .Aspartate transaminases (AST/SGOT) or alanine transaminase (ALT/SGPT) ≤ 2.5 times the upper limit.
• Patients must be able to take drugs and don't spit out, no malabsorption problem.
• Able to comply with study procedures and follow-up examinations.

Exclusion Criteria:

• Patients have known central nervous system metastasis except patients who have terminated steroid treatment for brain metastasis or spinal cord compression with remain disease stable for at least 1 month.
• Previous treatment with entinostat or any other histone deacetylase inhibitor (Valproic acid, Chidamide etc).
• Known allergy to any ingredients of entinostat and other drugs in the same class.
• Women who are pregnant or breast-feeding (premenopausal). For women of childbearing potential, agreement to use a medically approved contraception measures (such as the intrauterine device (IUD), birth control pills or condoms) and to continue its use for the duration of study treatment and for 3 months after the last dose of study treatment.
• Had received chemotherapy/radiotherapy or other anticancer therapy during the study or within 4 weeks of start of study treatment. Patients must completely recovered from all adverse events due to previous agents administered before 4 weeks (except alopecia).
• Major surgery within 28 days of start of study treatment.
• Patients have serious or uncontrolled systemic disease (such as severe liver dysfunction, severe renal dysfunction, poorly controlled diabetes, poorly controlled acute infections). Unstable or decompensated respiratory or cardiovascular disease, or peripheral vascular disease (including diabetic vascular disease), or organ transplantation.
• Received potent CYP1A2 or CYP3A4 inducer and/or inhibitor (including but not limited following drug: ketoconazole, rifampicin, atazanavir, Clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice, rifabutin, phenytoin, Carbamazepine and phenobarbital).
• Patients with another active cancer (excluding basal cell carcinoma or cervical intraepithelial neoplasia [cervical intraepithelial neoplasia （CIN）/cervical carcinoma in situ] or melanoma in-situ). Prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years.
• Active bleeding or new thrombotic diseases using of anticoagulant drugs, patients with bleeding tendency.
• Meet with any of the following criteria about cardiac parameters:
• the corrected QT interval (QTc) >470 msec under resting conditions.
• myocardial infarction or arterial thrombosis events within 6 months, or experiencing severe or unstable angina, or New York Heart Association (NYHA) Class III or IV disease.
• Resting ECG imply any clinically significant abnormal on rhythm, conduction and morphology, for example, left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec.
• Any factors (such as, heart failure, hypokalemia, inherited long QT syndrome, acquired long QT syndrome or family history of unexplained sudden death in immediate family members under 40 years old) or known combined drug (such as, sotalol, cisapride, clozapine, amiodarone and erythromycin, etc.) to increase risk of prolongation of QTc interval or arrhythmic event.
• History of or known human immunodeficiency virus (HIV) infection
• Known drug or long-term alcoholics.
• Patient is currently enrolled in (or completed within 30 days before study drug administration) another investigational drug study.
• Involvement in the planning and conduct of the study.
• Possible of lower inclusion criteria according to the researchers (such as weak, etc), or the other is not suitable for this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Entinostat and Exemestane; Patients receive entinostat PO on days 1, 8, 15, and 22. Entinostat in combination with exemestane will be repeatedly administered every 28 days in the absence of disease progression or unacceptable toxicity. Exemestane wil be orally administered once daily for up to six months.	Drug: Entinostat; Given PO; Other Names: MS-275; SDNX-275; Drug: Exemestane; Given PO

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Adverse events, 12-lead ECG, blood pressure/pulse, temperature, laboratory parameters and physical examination.	Up to 28 days

Secondary Outcome Measures

Outcome Measure	Time Frame
Cmax,maximum plasma concentration	Pre-dose, Days 1,2,3,4,5,7,15 and 22
tmax,time at which maximum plasma concentration was observed	Pre-dose, Days 1,2,3,4,5,7,15 and 22
AUC 0-168h area under the plasma concentration-time curve from time zero to 168h	Pre-dose, Days 1,2,3,4,5 and 7
AUC 0-inf,area under the plasma concentration-time curve from time zero to infinity	Pre-dose, Days 1,2,3,4,5,7,15 and 22
T1/2, elimination half-life	Pre-dose, Days 1,2,3,4,5,7,15 and 22
lambda z , apparent terminal phase elimination constant (λz)	Pre-dose, Days 1,2,3,4,5,7,15 and 22
MRT，mean residence time	Pre-dose, Days 1,2,3,4,5,7,15 and 22

Collaborators and Investigators

• Sponsor: Taizhou EOC Pharma Co., Ltd.

Publications and helpful links

General Publications

• Wang J, Zhang Q, Li Q, Mu Y, Jing J, Li H, Li W, Wang J, Yu G, Wang X, Ouyang Q, Hao J, Lu L, Zhou L, Guan J, Li Q, Xu B. Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. Target Oncol. 2021 Sep;16(5):591-599. doi: 10.1007/s11523-021-00823-4. Epub 2021 Jul 1.

Study record dates

Study Major Dates

• Study Start (Actual): August 29, 2016
• Primary Completion (Actual): July 18, 2018
• Study Completion (Actual): July 18, 2018

Study Registration Dates

• First Submitted: July 12, 2016
• First Submitted That Met QC Criteria: July 12, 2016
• First Posted (Estimate): July 14, 2016

Study Record Updates

• Last Update Posted (Actual): May 7, 2019
• Last Update Submitted That Met QC Criteria: May 3, 2019
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Keywords: breast cancer; entinostat
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hormone Antagonists; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Histone Deacetylase Inhibitors; Exemestane; Entinostat
• Other Study ID Numbers: EOC103-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided